PD Dr. med. Arndt Weinmann, MBA

Funktionen: Geschäftsführender Oberarzt, Leiter der Aufnahmekoordination und des klinischen Managements
Oberarzt in der HCC und onkologischen Ambulanz
Leiter Clinical Registry Unit (CRU)

Qualifikationen: Facharzt für Innere Medizin, medikamentöse Tumortherapie, medizinische Informatik, Gesundheitsökonom (ebs)

06131 17-2669
06131 17-472669
arndt.weinmann@unimedizin-mainz.de

Wissenschaftliche Schwerpunkte

Entwicklung und Aufbau klinischer Register zu verschiedenen Krankheitsentitäten, v.a. für die gastrointestinale Onkologie (HCC, cholangiozelluläres Karzinom, Pankreaskarzinom, GIST, kolorektales Karzinom, Magenkarzinom), Leberzirrhose, Hepatitis B, Hepatitis C und primär biliäre Zirrhose.

Systemmedizin des hepatozellulären Karzinoms und der Leberzirrhose.

Gesundheitsökonomie: Analyse der ärztlichen Arbeitszeit und Optimierung klinikinterner Prozesse. Implementierung einer Aufnahmekoordination zur Organisation elektiver Patientenaufnahmen und ökonomische Analyse der Auswirkungen.

Entwicklung prozessunterstützender Software.

Leiter der Clinical Registry Unit (CRU)

Arbeitsgruppe

Gesundheitsökonomie

• Frau Barbara Eisenmann de Torres,  E-Mail

Bioinformatik

• Frau Sandra Koch,  E-Mail

Doktoranden

• Franziska Bierling,  E-Mail
• Elena Heil,  E-Mail
• Jaqueline Heinz,  E-Mail (Betreuung mit Dr. Thomaidis)
• Lukas Pilz,  E-Mail
• Verena Steinle,  Email (Betreuung mit Dr. Klöckner)

Doktoranden gesucht

Für die Erweiterung unseres Client/Server-Systems suchen wir Doktoranden, die über umfassende Programmiererfahrung verfügen, idealerweise in Kombination mit Kenntnissen über SQL-Datenbanken.

Kooperationen

• Univ.-Prof. Dr. Hauke Lang, AVTC
• Univ.-Prof. Dr. Gerd Otto, Transplantationschirurgie
• Univ.-Prof. Dr. Christoph Düber, Diagnostische und interventionelle Radiologie
• Univ.-Prof. Dr. Michael Pitton, Diagnostische und interventionelle Radiologie
• Dr. Roman Klöckner, Diagnostische und interventionelle Radiologie
• Prof. Dr. med. Henning Schulze-Bergkamen, Wesel
• Univ.-Prof. Dr. med. Dr. rer nat. Andreas Teufel, Uniklinik Regensburg
• PD Dr. med. Marcus Wörns
• Univ.-Prof. Dr. Andreas Schwarting
• PD Dr. Julia Weinmann-Menke
• PD Dr. Jörn Schattenberg
• PD Dr. Martin Sprinzl
• Univ.-Prof. Dr. Harald Binder, IMBEI, Universitätsmedizin Mainz
• Dr. Irene Schmidtmann, IMBEi, Universitätsmedizin Mainz

Publikationen

• Castven D, Fischer M, Becker D, Heinrich S, Andersen JB, Strand D, Sprinzl MF, Strand S, Czauderna C, Heilmann-Heimbach S, Roessler S, Weinmann A, Wörns MA, Thorgeirsson SS, Galle PR, Matter MS, Lang H, Marquardt JU.
  Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas.
  Oncotarget. 2017 Mar 15. doi: 10.18632/oncotarget.16231.
• Mähringer-Kunz A, Kloeckner R, Pitton MB, Düber C, Schmidtmann I, Galle PR, Koch S, Weinmann A.
  Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma.
  Cardiovasc Intervent Radiol. 2017 Feb 14. doi: 10.1007/s00270-017-1606-4.
• Kloeckner R, Pinto Dos Santos D, Kreitner KF, Leicher-Düber A, Weinmann A, Mittler J, Düber C.
  Quantitative assessment of washout in hepatocellular carcinoma using MRI.
  BMC Cancer. 2016 Sep 29;16(1):758.
• Kloeckner R, Pitton MB, Dueber C, Schmidtmann I, Galle PR, Koch S, Wörns MA, Weinmann A.
  Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma.
  J Vasc Interv Radiol. 2016 Aug 22. pii: S1051-0443(16)30274-3. doi: 10.1016/j.jvir.2016.06.012.

• Moehler M, Mahlberg R, Heinemann V, Obermannová R, Kubala E, Melichar B, Weinmann A, Scigalla P, Tesařová M, Janda P, Hédouin-Biville F, Mansoor W.
  Phase I study of orally administered S-1 in combination with epirubicin and oxaliplatin in patients with advanced solid tumors and chemotherapy-naïve advanced or metastatic esophagogastric cancer.
  Gastric Cancer. 2016 Jun 2.

• Grimm D, Lieb J, Weyer V, Vollmar J, Darstein F, Lautem A, Hoppe-Lotichius M, Koch S, Schad A, Schattenberg JM, Wörns MA, Weinmann A, Galle PR, Zimmermann T.
  Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment.
  BMC Cancer. 2016 Feb 12;16(1):94.

• Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura S, Schweitzer N, Vogel A, Manns MP, Benckert J, Berg T, Ebker M, Best J, Dechêne A, Gerken G, Schlaak JF, Weinmann A, Wörns MA, Galle P, Yeo W, Mo F, Chan SL, Reeves H, Cox T, Johnson P.
  Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.

  Clin Gastroenterol Hepatol. 2016 Jan 13. pii: S1542-3565(16)00044-6. doi: 10.1016/j.cgh.2015.12.042.

• Zöller D, Schmidtmann I, Weinmann A, Gerds TA, Binder H.
  Stagewise pseudo-value regression for time-varying effects on the cumulative incidence. Stat Med. 2015 Oct 28. doi: 10.1002/sim.6770.

• Kloeckner R, Weinmann A, Prinz F, Pinto dos Santos D, Ruckes C, Dueber C, Pitton MB.
  Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer 2015 Jun 10;15:465. doi: 10.1186/s12885-015-1480-x.
• Weinmann A, Alt Y, Koch S, Nelles C, Düber C, Lang H, Otto G, Zimmermann T, Marquardt JU, Galle PR, Wörns MA, Schattenberg JM.
  Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. BMC Cancer. 2015 Apr 1;15:210. doi: 10.1186/s12885-015-1197-x.
• Rathmayer M, Scheffer H, Braun M, Heinlein W, Akoglu B, Brechmann T, Gölder SK, Lankisch T, Messmann H, Schneider A, Wagner M, Fleßa S, Meier A, Lewerenz B, Gossner L, Faiss S, Toermer T, Werner T, Wilke MH, Lerch MM, Schepp W; DRG-Arbeitsgruppe und das Zeiterfassungsprojekt der DGVS (Autoren im Anhang).
  [Improvement of cost allocation in gastroenterology by introduction of a novel service catalogue covering the complete spectrum of endoscopic procedures]. Z Gastroenterol. 2015 Mar;53(3):183-98. doi: 10.1055/s-0034-1399199. Epub 2015 Mar 16.
• Sprinzl MF, Puschnik A, Schlitter AM, Schad A, Ackermann K, Esposito I, Lang H, Galle PR, Weinmann A, Heikenwälder M, Protzer U.
  Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.
  J Hepatol. 2015 Apr;62(4):863-70. doi: 10.1016/j.jhep.2014.11.011. Epub 2014 Nov 22.
• Pitton MB, Kloeckner R, Ruckes C, Wirth GM, Eichhorn W, Wörns MA, Weinmann A, Schreckenberger M, Galle PR, Otto G, Dueber C.
  Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma.
  Cardiovasc Intervent Radiol. 2015 Apr;38(2):352-60. doi: 10.1007/s00270-014-1012-0. Epub 2014 Nov 7.
• Schmidtmann I, Elsäßer A, Weinmann A, Binder H.
  Coupled variable selection for regression modeling of complex treatment patterns in a clinical cancer registry.
  Stat Med. 2014 Dec 30;33(30):5358-70. doi: 10.1002/sim.6340. Epub 2014 Oct 27.
• Weinmann A, Koch S, Sprinzl M, Kloeckner R, Schulze-Bergkamen H, Düber C, Lang H, Otto G, Wörns MA, Galle PR.
  Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients.
  Liver Int. 2015 Feb;35(2):591-600. doi: 10.1111/liv.12696. Epub 2014 Oct 31.
• Thomaidis T, Maderer A, Formentini A, Bauer S, Trautmann M, Schwarz M, Neumann W, Kittner JM, Schad A, Link KH, Rey JW, Weinmann A, Hoffman A, Galle PR, Kornmann M, Moehler M.
  Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
  J Exp Clin Cancer Res. 2014 Oct 2;33:83. doi: 10.1186/s13046-014-0083-8.
• Moehler M, Thomaidis T, Zeifri C, Barhoom T, Marquardt J, Ploch P, Schattenberg J, Maderer A, Schimanski CC, Weinmann A, Woerns MA, Kranich AL, Warnecke JM, Galle PR.
  Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!
  J Cancer Res Clin Oncol. 2015 Mar;141(3):515-22. doi: 10.1007/s00432-014-1829-6. Epub 2014 Sep 19.
• Kloeckner R, Ruckes C, Kronfeld K, Wörns MA, Weinmann A, Galle PR, Lang H, Otto G, Eichhorn W, Schreckenberger M, Dueber C, Pitton MB.
  Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial.
  Trials. 2014 Aug 6;15:311. doi: 10.1186/1745-6215-15-311.
• Weinmann A, Sattler T, Unold HP, Grambihler A, Teufel A, Koch S, Schuchmann M, Biesterfeld S, Wörns MA, Galle PR, Schulze-Bergkamen H.
  Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.
  J Clin Gastroenterol. 2015 May-Jun;49(5):438-47. doi: 10.1097/MCG.0000000000000176.
• Menke J, Amann K, Cavagna L, Blettner M, Weinmann A, Schwarting A, Kelley VR.
  Colony-stimulating factor-1: a potential biomarker for lupus nephritis.
  J Am Soc Nephrol. 2015 Feb;26(2):379-89. doi: 10.1681/ASN.2013121356. Epub 2014 Jul 10.
• Sprinzl MF, Russo C, Kittner J, Allgayer S, Grambihler A, Bartsch B, Weinmann A, Galle PR, Schuchmann M, Protzer U, Bauer T.
  Hepatitis B virus-specific T-cell responses during IFN administration in a small cohort of chronic hepatitis B patients under nucleos(t)ide analogue treatment.
  J Viral Hepat. 2014;21(9):633-41. doi: 10.1111/jvh.12189. Epub 2013 Nov 19.
• Greten TF, Malek NP, Schmidt S, Arends J, Bartenstein P, Bechstein W, Bernatik T, Bitzer M, Chavan A, Dollinger M, Domagk D, Drognitz O, Düx M, Farkas S, Folprecht G, Galle P, Geißler M, Gerken G, Habermehl D, Helmberger T, Herfarth K, Hoffmann RT, Holtmann M, Huppert P, Jakobs T, Keller M, Klempnauer J, Kolligs F, Körber J, Lang H, Lehner F, Lordick F, Lubienski A, Manns MP, Mahnken A, Möhler M, Mönch C, Neuhaus P, Niederau C, Ocker M, Otto G, Pereira P, Pott G, Riemer J, Ringe K, Ritterbusch U, Rummeny E, Schirmacher P, Schlitt HJ, Schlottmann K, Schmitz V, Schuler A, Schulze-Bergkamen H, von Schweinitz D, Seehofer D, Sitter H, Straßburg CP, Stroszczynski C, Strobel D, Tannapfel A, Trojan J, van Thiel I, Vogel A, Wacker F, Wedemeyer H, Wege H, Weinmann A, Wittekind C, Wörmann B, Zech CJ.
  [Diagnosis of and therapy for hepatocellular carcinoma].
  Z Gastroenterol. 2013 Nov;51(11):1269-326. doi: 10.1055/s-0033-1355841. Epub 2013 Nov 15. German.
• Wörns MA, Klöckner R, Weinmann A, Galle PR.
  [Therapy of hepatocellular carcinoma].
  Internist (Berl). 2014 Jan;55(1):23-4, 26-30. doi: 10.1007/s00108-013-3318-4.
• Kittner JM, Weiss NM, Wiltink J, Schattenberg JM, Grambihler A, Thieringer F, Weinmann A, Zimmermann T, Koch S, Schuchmann M, Galle PR.
  Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents.
  Dig Liver Dis. 2014 Jan;46(1):67-71. doi: 10.1016/j.dld.2013.08.139. Epub 2013 Oct 12.
• Weinmann A, Koch S, Niederle IM, Schulze-Bergkamen H, König J, Hoppe-Lotichius M, Hansen T, Pitton MB, Düber C, Otto G, Schuchmann M, Galle PR, Wörns MA.
  Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.
  J Clin Gastroenterol. 2014 Mar;48(3):279-89. doi: 10.1097/MCG.0b013e3182a8a793.
• Staib F, Krupp M, Maass T, Itzel T, Weinmann A, Lee JS, Schmidt B, Müller M, Thorgeirsson SS, Galle PR, Teufel A.
  CellMinerHCC: a microarray-based expression database for hepatocellular carcinoma cell lines.
  Liver Int. 2014 Apr;34(4):621-31. doi: 10.1111/liv.12292. Epub 2013 Sep 9.
• Scheuermann U, Kaths JM, Heise M, Pitton MB, Weinmann A, Hoppe-Lotichius M, Otto G.
  Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience.
  Eur J Surg Oncol. 2013 Jun;39(6):593-600. doi: 10.1016/j.ejso.2013.03.010. Epub 2013 Apr 20.
• Otto G, Schuchmann M, Hoppe-Lotichius M, Heise M, Weinmann A, Hansen T, Pitton MP.
  How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE?
  J Hepatol. 2013 Aug;59(2):279-84. doi: 10.1016/j.jhep.2013.04.006. Epub 2013 Apr 12.
• Thomaidis T, Weinmann A, Sprinzl M, Kanzler S, Raedle J, Ebert M, Schimanski CC, Galle PR, Hoehler T, Moehler M; Upper-GI-Group of AIO (Arbeitsgemeinschaft Internistische Onkologie), Germany.
  Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients.
  Int J Clin Oncol. 2014 Apr;19(2):288-96. doi: 10.1007/s10147-013-0544-7. Epub 2013 Mar 27.
• Sprinzl MF, Reisinger F, Puschnik A, Ringelhan M, Ackermann K, Hartmann D, Schiemann M, Weinmann A, Galle PR, Schuchmann M, Friess H, Otto G, Heikenwalder M, Protzer U.
  Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
  Hepatology. 2013 Jun;57(6):2358-68. doi: 10.1002/hep.26328.
• Wörns MA, Koch S, Niederle IM, Marquardt JU, Nguyen-Tat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H, Galle PR, Weinmann A.
  The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
  Dig Liver Dis. 2013 May;45(5):408-13. doi: 10.1016/j.dld.2012.10.010. Epub 2012 Nov 21.
• Sprinzl MF, Weinmann A, Lohse N, Tönissen H, Koch S, Schattenberg J, Hoppe-Lotichius M, Zimmermann T, Galle PR, Hansen T, Otto G, Schuchmann M.
  Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation.
  Transpl Int. 2013 Jan;26(1):67-74. doi: 10.1111/j.1432-2277.2012.01576.x. Epub 2012 Nov 5.
• Niederle IM, Wörns MA, Koch S, Nguyen-Tat M, Düber C, Otto G, Schuchmann M, Galle PR, Weinmann A.
  Clinicopathologic features and prognosis of young patients with hepatocellular carcinoma in a large German cohort.
  J Clin Gastroenterol. 2012 Oct;46(9):775-8. doi: 10.1097/MCG.0b013e31826102cc.
• Skowasch M, Schneider J, Otto G, Weinmann A, Woerns MA, Dueber C, Pitton MB.
  Midterm follow-up after DC-BEAD™-TACE of hepatocellular carcinoma (HCC).
  Eur J Radiol. 2012 Dec;81(12):3857-61. doi: 10.1016/j.ejrad.2012.07.002. Epub 2012 Jul 25.
• Wörns MA, Bosslet T, Victor A, Koch S, Hoppe-Lotichius M, Heise M, Hansen T, Pitton MB, Niederle IM, Schuchmann M, Weinmann A, Düber C, Galle PR, Otto G.
  Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver.
  Scand J Gastroenterol. 2012 Jun;47(6):718-28. doi: 10.3109/00365521.2012.677952. Epub 2012 Apr 4.
• Kittner JM, Sprinzl MF, Grambihler A, Weinmann A, Schattenberg JM, Galle PR, Schuchmann M.
  Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B.
  J Clin Virol. 2012 May;54(1):93-5. doi: 10.1016/j.jcv.2012.01.024. Epub 2012 Feb 24.
• Weinmann A, Niederle IM, Koch S, Hoppe-Lotichius M, Heise M, Düber C, Schuchmann M, Otto G, Galle PR, Wörns MA.
  Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
  Dig Liver Dis. 2012 May;44(5):432-7. doi: 10.1016/j.dld.2011.12.009. Epub 2012 Jan 20.
• Gamstätter T, Weinmann A, Schadmand-Fischer S, Spies PR, Niederle IM, Schuchmann M, Galle PR, Wörns MA.
  AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature. Onkologie. 2011;34(10):538-42. Epub 2011 Sep 16.
• Wörns MA, Schuchmann M, Düber C, Otto G, Galle PR, Weinmann A.
  Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology. 2010;79(1-2):85-92. Epub 2010 Nov 12.
• Buchkremer S, Hendel J, Krupp M, Weinmann A, Schlamp K, Maass T, Staib F, Galle PR, Teufel A.
  Library of molecular associations: curating the complex molecular basis of liver diseases. BMC Genomics. 2010 Mar 20;11:189.
• Teufel A, Weinmann A, Kahaly GJ, Centner C, Piendl A, Wörns M, Lohse AW, Galle PR, Kanzler S. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol. 2010 Mar;44(3):208-13.
• Wörns MA, Weinmann A, Schuchmann M, Galle PR.
  Systemic therapies in hepatocellular carcinoma. Dig Dis. 2009;27(2):175-88. Epub 2009 Jun 22. Review.
• Schulze-Bergkamen H, Weinmann A, Moehler M, Siebler J, Galle PR.
  Novel ways to sensitise gastrointestinal cancer to apoptosis. Gut. 2009 Jul;58(7):1010-24. Review.
• Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, Teufel A, Schuchmann M, Kanzler S, Düber C, Otto G, Galle PR. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol. 2009 May-Jun;43(5):489-95.
• Teufel A, Weinmann A, Centner C, Piendl A, Lohse AW, Galle PR, Kanzler S.
  Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol. 2009 Feb 7;15(5):578-82.
• Schlamp K, Weinmann A, Krupp M, Maass T, Galle P, Teufel A.
  BlotBase: a northern blot database. Gene. 2008 Dec 31;427(1-2):47-50. Epub 2008 Sep 18.
• Teufel A, Staib F, Kanzler S, Weinmann A, Schulze-Bergkamen H, Galle PR
  Genetics of hepatocellular carcinoma. World J Gastroenterol. 2007 Apr 28;13(16):2271-82. Review.
• Teufel A, Weinmann A, Krupp M, Budinger M, Galle PR
  Genome-wide analysis of factors regulating gene expression in liver. Gene 2007 Nov 7;. Pubmed
• Teufel A, Worns M, Weinmann A, Centner C, Piendl A, Lohse A, Galle P, Kanzler S.Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients. World J Gastroenterol 2006 September;12(34):5513-5516
• Teufel, A., Krupp, M., Weinmann, A., Galle, P. R. (2006) Current bioinformatics tools in genomic biomedical research (Review). Int J Mol Med 17: 967-973.
• Schuchmann, M., Schulze-Bergkamen, H., Fleischer, B., Schattenberg, J. M., Siebler, J., Weinmann, A., Teufel, A., Worns, M., Fischer, T., Strand, S., Lohse, A. W., Galle, P. R. (2006) Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 15: 227-230.
• Krupp, M., Weinmann, A., Galle, P. R., Teufel, A. (2006) Actin binding LIM protein 3 (abLIM3). Int J Mol Med 17: 129-133.
• Weinmann, A., Galle, P. R., Teufel, A. (2005) In silico characterization of an Iroquois family-related homeodomain protein. Int J Mol Med 16: 443-448.
• Weinmann, A., Galle, P. R., Teufel, A. (2005) LASS6, an additional member of the longevity assurance gene family. Int J Mol Med 16: 905-910.
• Teufel, A., Weinmann, A., Galle, P. R., Lohse, A. W. (2005) Characterization of OEBT, a LIM protein. Int J Mol Med 15: 513-518.
• Teufel, A., Weinmann, A., Galle, P. R., Lohse, A. W. (2005) In silico characterization of LZTS3, a potential tumor suppressor. Oncol Rep 14: 547-551.